144 related articles for article (PubMed ID: 23768069)
21. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
23. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
24. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.
Rysz J; Banach M; Stolarek RA; Mikhailidis DP; Cialkowska-Rysz A; Pokoca L; Piechota M; Baj Z
Int Urol Nephrol; 2011 Jun; 43(2):491-8. PubMed ID: 19953348
[TBL] [Abstract][Full Text] [Related]
25. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
26. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
Stojanovic N; Lewandowski K; Salata I; Bienkiewicz M; Tuck S; Prelevic G; Press M
Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
29. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
30. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
31. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
Castellazzi M; Bellini T; Trentini A; Delbue S; Elia F; Gastaldi M; Franciotta D; Bergamaschi R; Manfrinato MC; Volta CA; Granieri E; Fainardi E
Dis Markers; 2016; 2016():8434209. PubMed ID: 27340316
[TBL] [Abstract][Full Text] [Related]
32. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer.
Vasala K; Kuvaja P; Turpeenniemi-Hujanen T
Tumour Biol; 2008; 29(5):279-86. PubMed ID: 18802398
[TBL] [Abstract][Full Text] [Related]
33. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
34. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
[TBL] [Abstract][Full Text] [Related]
35. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
37. MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates.
Schulz CG; Sawicki G; Lemke RP; Roeten BM; Schulz R; Cheung PY
Pediatr Res; 2004 May; 55(5):794-801. PubMed ID: 14973177
[TBL] [Abstract][Full Text] [Related]
38. Lipid Peroxidation, Protein Oxidation, Gelatinases, and Their Inhibitors in a Group of Adults with Obesity.
Caimi G; Canino B; Montana M; Urso C; Calandrino V; Presti RL; Hopps E
Horm Metab Res; 2019 Jun; 51(6):389-395. PubMed ID: 31075797
[TBL] [Abstract][Full Text] [Related]
39. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
[TBL] [Abstract][Full Text] [Related]
40. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.
Hopps E; Lo Presti R; Montana M; Noto D; Averna MR; Caimi G
J Investig Med; 2013 Aug; 61(6):978-83. PubMed ID: 23661104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
